The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study
Sign Up to like & getrecommendations! Published in 2020 at "Hepatology International"
DOI: 10.1007/s12072-020-10019-z
Abstract: Background Direct-acting anti-virals (DAAs) have markedly improved the effectiveness of anti-viral therapy for chronic hepatitis C (CHC) patients. In a phase III trial in Japan, treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A… read more here.
Keywords: ckd stage; safety; genotype; refractory factors ... See more keywords